Anthem Blue Cross Blue Shield / Elevance (Commercial) · intrathecal drug delivery
✓ conditional · commercial
Criteria checklist
0 of 5 ticked- enumerated: yes
- covered:
- name: Severe chronic intractable pain (malignant or nonmalignant)
- criteria:
- trial: successful trial of opioid/nonopioid analgesic by the SAME route (intrathecal/epidural); >=50% pain reduction (binding)
- name: Severe spasticity
- criteria:
- drug: intrathecal baclofen after failure of oral baclofen
- name: Other labeled uses (cancer pain, pulmonary arterial hypertension, hepatic-artery chemotherapy)
- required: yes
- min duration months: not stated in the policy
- satisfied by:
- failed less-invasive therapy
- successful intrathecal trial
- modalities named:
- systemic/oral analgesics
- oral baclofen (spasticity)
- required: yes
- min duration days: not stated in the policy
- success criteria:
- logic: pain_reduction
- pain reduction pct: 50
- threshold is binding: yes
- required: no
- must clear: no
- note posture: not a stated gate in CG-SURG-79
- applies: yes
- replacement: catheter codes 62350/62351/62360 MN when the pump is MN
Anthem CG-SURG-79 covers implantable intrathecal pumps for severe chronic intractable pain (malignant/nonmalignant) after a SUCCESSFUL same-route analgesic trial (>=50% reduction, binding), plus spasticity (IT baclofen after oral failure) and other labeled uses. Like Medicare NCD 280.14, the trial is the gate (no fixed conservative-care month floor). From the fetched CG-SURG-79 (VA instance of the national guideline — confirm local instance; needs_reverification).
Ticks are a documentation aid — nothing is stored; they reset on reload.
Dot phrase
Lean narrative A&P attestation. `***` = fill-in. Maps to Anthem CG-SURG-79. Two blocks — pick one. The same-route analgesic trial is the gate — CG-SURG-79 sets no fixed conservative-care month floor, no psych-eval gate, and no life-expectancy requirement. (The policy also enumerates other labeled uses — cancer pain, pulmonary arterial hypertension, hepatic-artery chemotherapy — with no per-use gates recorded.)
.ITDDANTHEM [PAIN] Assessment: *** — severe chronic intractable pain (malignant / nonmalignant) of *** etiology, refractory to less-invasive therapy including systemic and oral analgesics. Medical necessity per Anthem CG-SURG-79 (Implantable Infusion Pumps): less-invasive therapy with systemic and oral analgesics has failed; the policy sets no fixed duration floor, and the qualifying gate is the trial. A preliminary trial of an opioid or nonopioid analgesic by the same route as the planned permanent infusion (intrathecal/epidural) was performed on *** with >=50% pain reduction, as required before permanent pump implantation. Plan: Implantation of a programmable intrathecal drug-delivery pump and catheter (62362 + 62350). Risks, benefits, and alternatives discussed; consent obtained. --- .ITDDANTHEM [SPASTICITY] — swap the assessment and trial sentences: Assessment: *** — severe spasticity of *** etiology. Oral baclofen has failed, and the pump is being implanted to deliver intrathecal baclofen.
Where this payor diverges from the Medicare baseline
Cautions
Prior-auth pathway
- required: yes
- pathway: Anthem precertification (implantable device)
Provenance
- authority:
- type: commercial_policy
- id: Anthem CG-SURG-79
- title: Implantable Infusion Pumps
- applies because: Anthem clinical UM guideline governs implantable intrathecal drug-delivery pumps
- source: https://www.anthem.com/dam/medpolicies/abcbs_va/active/guidelines/gl_pw_d080206.html
- effective: 2025-10-01 · payor last reviewed: 2025-08-07 · we verified: 2026-07-24 · v1
Change history
- 2026-07-24anthem pns/reactiv8/itdd: verified live via browser (JS-gated HTML) - SURG.00158 + CG-SURG-79 dates & criteria unchanged; last_verified 2026-07-24 (itdd needs_reverification kept: local-instance adoption unconfirmable)
6ab4f64dcd - 2026-06-29Add commercial ITDD cells: Anthem, UHC, Cigna (all covered)
3a15b25784